FDA Approves LINZESS for Functional Constipation in Children as Young as 2 Years Old
核心洞察
The FDA has approved LINZESS (linaclotide) for treating functional constipation (搜索) in pediatric patients aged 2 years and older, expanding from the previous minimum age of 6 years.
LINZESS remains the only FDA-approved prescription therapy for pediatric functional constipation (搜索), a chronic condition affecting an estimated 3% of preschool children worldwide.
The approval was supported by a 12-week Phase 3 randomized, placebo-controlled trial showing improved spontaneous bowel movement frequency with LINZESS 72 mcg compared to placebo.
Ironwood Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the use of LINZESS (linaclotide) in pediatric patients 2 years of age and older with functional constipation (搜索), expanding the drug's indication from the previous minimum age of 6 years. This approval makes LINZESS the only FDA-approved prescription therapy for pediatric functional constipation.
Addressing an Unmet Medical Need
Functional constipation (搜索) in children is a chronic condition characterized by hard, infrequent bowel movements that are often difficult or painful to pass. The condition is common among preschool children, with an estimated worldwide prevalence of 3% that may vary by geographic region.
"Managing functional constipation (搜索) in young children is especially challenging, as this vulnerable patient population often continues to experience persistent symptoms despite treatment with over-the-counter therapies," said Dr. Julie Khlevner, a pediatric gastroenterologist at Columbia University Vagelos College of Physicians and Surgeons. "Clinicians must carefully balance safety, efficacy and the practical realities of what treatments young children are able and willing to take consistently."
Clinical Trial Results
The FDA approval for pediatric patients ages 2-5 was supported by data from a 12-week Phase 3 randomized, placebo-controlled clinical trial evaluating LINZESS in pediatric patients aged 2-5 years with functional constipation (搜索). In the study, LINZESS 72 mcg demonstrated improvement in spontaneous bowel movement frequency compared with placebo.
The safety profile of LINZESS observed in the trial was generally consistent with the established safety profile from trials in adults with chronic idiopathic constipation (搜索) and older pediatric patients with functional constipation (搜索).
Treatment Flexibility for Young Patients
The approval provides important practical advantages for treating young children. Parents can mix the contents of the LINZESS capsule with applesauce or water, providing flexibility for administration in young children who may have difficulty swallowing capsules.
"The availability of an FDA-approved therapy with an established safety profile expands evidence-based treatment options and may support a more tailored therapeutic approach for children aged 2-5 years," Dr. Khlevner noted.
Market Impact and Company Perspective
Tom McCourt, chief executive officer of Ironwood, emphasized the significance of this approval: "This approval extends the use of LINZESS to younger patients with functional constipation (搜索), addressing an important gap in care for this historically underserved population, as reflected by the FDA's decision to grant priority review."
Since its launch in 2012, LINZESS has been prescribed to treat more than 5.5 million unique patients and is the prescription market leader for the treatment of IBS-C and adults with chronic idiopathic constipation (搜索). LINZESS 72mcg is available as a once-daily treatment with accessibility for most patients building on established class-leading formulary coverage already in place for the brand.
About LINZESS
LINZESS is the #1 prescribed brand in the U.S. for the treatment of patients with irritable bowel syndrome with constipation (搜索) or chronic idiopathic constipation (搜索), based on IQVIA data. The drug is not a laxative but is the first medicine approved by the FDA in a class called GC-C agonists. LINZESS contains a peptide called linaclotide that activates the GC-C receptor (搜索) in the intestine, resulting in increased intestinal fluid secretion and accelerated transit.
In the United States, Ironwood and AbbVie (搜索) co-develop and co-commercialize LINZESS for multiple indications including the treatment of IBS-C in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation (搜索) in adults, and functional constipation (搜索) in pediatric patients 2 years of age and older.